Literature DB >> 27026295

Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections.

Agnieszka Krzyzanowska1, Giuseppe Lippolis1, Leszek Helczynski2, Aseem Anand1, Mari Peltola3, Kim Pettersson3, Hans Lilja4,5,6, Anders Bjartell1,7.   

Abstract

Androgen receptor (AR) and prostate-specific antigen (PSA) are expressed in the prostate and are involved in prostate cancer (PCa). The aim of this study was to develop reliable protocols for reproducible quantification of AR and PSA in benign and malignant prostate tissue using time-resolved fluorescence (TRF) imaging techniques. AR and PSA were detected with TRF in tissue microarrays from 91 PCa patients. p63/ alpha-methylacyl-CoA racemase (AMACR) staining on consecutive sections was used to categorize tissue areas as benign or cancerous. Automated image analysis was used to quantify staining intensity. AR intensity was significantly higher in AMACR+ and lower in AMACR- cancer areas as compared with benign epithelium. The PSA intensity was significantly lower in cancer areas, particularly in AMACR- glands. The AR/PSA ratio varied significantly in the AMACR+ tumor cells as compared with benign glands. There was a trend of more rapid disease progression in patients with higher AR/PSA ratios in the AMACR- areas. This study demonstrates the feasibility of developing reproducible protocols for TRF imaging and automated image analysis to study the expression of AR and PSA in benign and malignant prostate. It also highlighted the differences in AR and PSA protein expression within AMACR- and AMACR+ cancer regions.
© 2016 The Histochemical Society.

Entities:  

Keywords:  androgen receptor; biomarkers; digital image analysis; prostate cancer; prostate-specific antigen; time-resolved fluorescence imaging

Mesh:

Substances:

Year:  2016        PMID: 27026295      PMCID: PMC4851272          DOI: 10.1369/0022155416640466

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  40 in total

1.  A europium chelate for quantitative point-of-care immunoassays using direct surface measurement.

Authors:  Piia von Lode; Jaana Rosenberg; Kim Pettersson; Harri Takalo
Journal:  Anal Chem       Date:  2003-07-01       Impact factor: 6.986

2.  Time-resolved fluorescence imaging of europium chelate label in immunohistochemistry and in situ hybridization.

Authors:  L Seveus; M Väisälä; S Syrjänen; M Sandberg; A Kuusisto; R Harju; J Salo; I Hemmilä; H Kojola; E Soini
Journal:  Cytometry       Date:  1992

Review 3.  Digital pathology: current status and future perspectives.

Authors:  Shaimaa Al-Janabi; André Huisman; Paul J Van Diest
Journal:  Histopathology       Date:  2011-04-11       Impact factor: 5.087

4.  Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.

Authors:  Susanna Lintula; Jakob Stenman; Anders Bjartell; Stig Nordling; Ulf-Håkan Stenman
Journal:  Prostate       Date:  2005-06-01       Impact factor: 4.104

5.  Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.

Authors:  Takahiro Inoue; Takehiko Segawa; Taizou Shiraishi; Toru Yoshida; Yoshinobu Toda; Tomomi Yamada; Naoko Kinukawa; Hidefumi Kinoshita; Toshiyuki Kamoto; Osamu Ogawa
Journal:  Urology       Date:  2005-08       Impact factor: 2.649

6.  Time-resolved fluorescence imaging of islet cell autoantibodies.

Authors:  Pauli Vuorinen; Maris Rulli; Ari Kuusisto; Satu Simell; Tuula Simell; Tero Vahlberg; Jorma Ilonen; Heikki Hyöty; Mikael Knip; Olli Simell
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

7.  Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.

Authors:  P Siivola; K Pettersson; T Piironen; T Lövgren; H Lilja; A Bjartell
Journal:  Urology       Date:  2000-10-01       Impact factor: 2.649

Review 8.  A role for the androgen-receptor in clinically localized and advanced prostate cancer.

Authors:  James L Mohler
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

9.  High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.

Authors:  Rile Li; Thomas Wheeler; Hong Dai; Anna Frolov; Timothy Thompson; Gustavo Ayala
Journal:  Am J Surg Pathol       Date:  2004-07       Impact factor: 6.394

10.  Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.

Authors:  Helena Tassidis; Leon J S Brokken; Karin Jirström; Roy Ehrnström; Fredrik Pontén; David Ulmert; Anders Bjartell; Pirkko Härkönen; Anette Gjörloff Wingren
Journal:  Int J Cancer       Date:  2010-05-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.